MED DISCOVERY SA
Route de la Corniche 4
1066 Epalinges - Switzerland
Tél +41 21 651 90 76 - Email
Founder and CEO of Med Discovery, Dr. Deperthes obtained his Ph.D. in Molecular and Cellular Biology from Laval University in Canada. Discoverer of a new prostate cancer marker, the kallikrein hK2, with Prof. Rolland R. Tremblay, he specialized in the development of new molecules for tumor targeting with J.P. Mach at the ISREC in Lausanne. Dr. Deperthes was Director of the Urology Research Unit at the University Hospital of Lausanne for 5 years. He won the NETS’ Prize in 2003 which consists of an intensive business and management training given at Babson College in Boston to a young entrepreneur selected by the NETS’ prize committee. Dr. Deperthes is also involved in different committees and associations such as Venturekick, Bioalps, or the Swiss Biotech Association.
Dr. Cloutier obtained his Ph.D. in Biochemistry (2002) at Lausanne University. From 2000 to 2002, he was Laboratory Head of the Urology Research Unit at the University Hospital CHUV in Lausanne working on the prostate cancer-specific marker human kallikrein 2 (hK2). Then, as a co-founder and Laboratory Head of Med Discovery, he developed Med Discovery's protease inhibitor technology platform, and using this, the recombinant protease inhibitor MDPK67b, targeting hK2 for the treatment of prostate cancer. Since 2005, he works at Anapharm, a Pharmanet company, located in Canada. Anapharm is a CRO (Clinical Research Organization) Specialized in Clinical development. Dr Cloutier was recently promoted as Clinical Director.
Dr. Christian Gygi, co-founder, is a staff member of the Urology Clinic and is one of the founders of the URU. Graduate of the University of Geneva, Switzerland, (1993) he worked for 2 years at Ely Lilly (Indianapolis, USA) where he exclusively engaged in research in the field of prostate carcinoma.
Co-founder, graduate of the University of Geneva, Switzerland (1988), is a associate professor and Head of the Department of Urology at CHUV in Lausanne, Switzerland. He has a special interest in photodynamic applications of bladder cancer in collaboration with the Swiss Federal Institute of Technology : LPAS-Prof H. van den Bergh. In addition, he is currently involved in a clinical research program with Photocure Inc (Netherlands).
Co-founder of Med Discovery, Professor Leisinger is a graduate of the University of Zurich, Switzerland (1972), Chairman and Head of the Urology Department of CHUV in Lausanne, Switzerland. Since 1992, he has been working in the field of oncologic and reconstructive urology and introduced modern surgical methods in the treatment of localized prostate and bladder cancers.
Professor Chagas obtained his Ph.D. in Molecular Biology from the Federal University of São Paulo, Brazil (1991), where he held an Assistant Professor position from 1992. From 1994 to 1996 he also worked as post-doctoral fellow in the University of Tours, France. From 1999 to 2006, as full Professor and Pro-Rector of Research and Graduate Courses in the University of Mogi das Cruzes, São Paulo, Brazil, he was in charge of creating research facilities and graduate courses on Biotechnology and Biomedical Engineering. In 2006 he moved back to the Federal University of São Paulo in its new campus at Santos, a city on the coast of São Paulo State, to participate in the creation of the new Health Sciences facilities, devoted to undergraduate, graduate and research activities.